Synthetic protein science platform for artificial molecule design
Location: United States, Washington, Seattle
Total raised: $121M
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.06.2024 | Series A | $71M | - |
| 29.08.2022 | Series A | $50M | - |
Mentions in press and media 3
| Date | Title | Description |
| 05.06.2024 | Vilya Expands Series A Financing to $71M | Vilya, a Seattle, WA-based biotechnology company creating a new class of medicines that precisely target disease biology, expanded its Series A funding to $71M. The round was led by ARCH Venture Partners with participation from NVentures, M... |
| 29.08.2022 | Sneaky synthetic molecules open the way for new types of drugs and a new startup | An illustration shows how custom-made peptide molecules (shown in pink and purple) can slip through a cell membrane. (Image by Ian C. Haydon / UW Institute for Protein Design) Researchers at the University of Washington have discovered how ... |
| 29.08.2022 | Vilya Launches With $50M in Series A Financing | Vilya, Inc., a Seattle, WA-based biotechnology company creating a new class of medicines that precisely target disease biology, launched with $50m in Series A financing. The round was led by ARCH Venture Partners. The company’s proprietary ... |